<DOC>
	<DOCNO>NCT00757250</DOCNO>
	<brief_summary>The purpose study test safety investigational medication , TXA127 , ability increase T-lymphocyte count , specifically CD4+ T-lymphocytes , person infect human immunodeficiency virus take highly active anti-retroviral therapy .</brief_summary>
	<brief_title>Safety Study TXA127 Elevate CD4+ T-Lymphocyte Counts HIV-Infected Patients Stable HAART Therapy</brief_title>
	<detailed_description>This Phase I , single institution , open-label , within-dosing-cohort-schedule randomize , dose escalation study TXA127 HIV-infected subject CD4+ T-lymphocyte count less 250 per mm3 respond highly active retroviral therapy ( HAART ) . The study design determine maximum tolerate dose ( MTD ) TXA127 subject population . This study also obtain safety biologic activity information subcutaneous injection TXA127 . Five escalate dose cohort examine determine MTD . The first four dosing cohort receive 50 , 100 , 200 300 mcg/kg TXA127 subcutaneous injection daily 14 day , follow 14 day without treatment . These 28 day define one cycle . The cycle therapy repeat , total two course treatment . The 5th dose cohort receive 300 mcg/kg TXA127 subcutaneous injection daily 28 day , 14 day without treatment follow additional 28 day TXA127 administration . Dose escalation next cohort subject permit next high dose level provide follow criterion meet . A standard Simon Phase I dose escalation trial propose . The MTD exceed proportion subject develop similar study-drug-related , DLT assign dose schedule equal 2/2 , 2/3 , 2/4 , 2/5 , 2/6 subject . The MTD define large dose &lt; 2 6 subject experience DLT . Dose-limiting toxicity define study-drug-related grade 3 4 adverse event ( AE ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>HIVinfected male nonpregnant , nonbreastfeeding female &gt; = 18 year age ; CD4+ Tlymphocyte count le 250 per mm3 ; Successful response HAART ( define HIV RNA viral load &lt; 50 copy per mL ) minimum one year precede study enrollment . Opportunistic infection within 6 month prior study enrollment Active tuberculosis mycobacterial infection Uncontrolled high blood pressure congestive heart failure class III IV Systemic glucocorticoid immunomodulator therapy within 30 day study entry Prior history Kaposi 's sarcoma Prior history lymphoma Active substance abuse within last 30 day Uncontrolled psychiatric disorder , include depression Abnormal inadequate liver renal function Inadequate bone marrow function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>CD4+ T-lymphocytes</keyword>
	<keyword>treatment Experienced</keyword>
</DOC>